metformin has been researched along with incretins in 124 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (8.06) | 29.6817 |
| 2010's | 98 (79.03) | 24.3611 |
| 2020's | 16 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Krentz, AJ | 1 |
| Aschner, P; Davies, MJ; Karasik, A; Katzeff, H; Stein, PP | 1 |
| Cefalu, WT; Urquhart, S | 1 |
| Inzucchi, SE | 1 |
| Gabbay, Mde A | 1 |
| Halimi, S | 2 |
| Fabreegas, B | 1 |
| Debaty, I; Halimi, S; Muller, M; Villaret, L | 1 |
| Barnett, AH; Piya, MK; Tahrani, AA | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Meier, JJ; Menge, BA; Schmidt, WE | 1 |
| Freeman, JS | 2 |
| Radermecker, RP; Scheen, AJ | 1 |
| Meier, JJ; Nauck, MA | 1 |
| Deaton, C; Gibson, JM; Mamas, MA; New, J; Neyses, L; Ray, SG; Rutter, MK; Williams, SG; Yuille, M | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| Shomali, M | 1 |
| Cariou, B; Charbonnel, B | 1 |
| Seyoum, B | 1 |
| Gu, Q; Patel, BV; Tripoli, LC; Zeng, F | 1 |
| Hamaty, M | 1 |
| Freeman, JS; Gavin, JR; Lavernia, F; Shubrook, JH | 1 |
| Bain, SC; Bodvarsdottir, TB; Bracken, RM; Deacon, CF; Dunseath, G; Holst, JJ; Lowe, GD; Luzio, S; Prior, SL; Rumley, A; Stephens, JW; Wareham, K | 1 |
| Barboza, J; Sando, KR; Taylor, J; Willis, C | 1 |
| Jermendy, G | 2 |
| Albiero, M; Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Menegazzo, L | 1 |
| Corsi, A; Ponzani, P | 1 |
| Spollett, GR | 1 |
| Bell, DS | 1 |
| Bain, SC; Damci, T; Dzida, G; Hollander, P; Meneghini, LF; Ross, SA; Vora, J | 1 |
| Kautzky-Willer, A; Lemmens-Gruber, R | 1 |
| Coester, HV; Forst, T; Hincelin-Méry, A; Kapitza, C; Poitiers, F; Ruus, P | 1 |
| Gonnelli, S; Montagnani, A | 1 |
| Kopecky, C | 1 |
| Cornell, SA | 1 |
| Boland, CL; Degeeter, M; Nuzum, DS; Tzefos, M | 1 |
| Allen, E; Fleming, D; Frederich, R; Karyekar, CS; Ravichandran, S | 1 |
| Marcy, TR; Zhao, Q | 1 |
| Bailey, T | 1 |
| Gallagher, EJ; LeRoith, D | 1 |
| Bajuk Studen, K; Jensterle Sever, M; Pfeifer, M | 1 |
| Bennett, K; Williams, D; Zaharan, NL | 1 |
| Arndt, E; Deacon, CF; Holst, JJ; Nauck, MA; Vardarli, I | 1 |
| Abate, N; Montalto, G; Nikolic, D; Rizvi, AA; Rizzo, M; Sallam, HS | 1 |
| Berthold, HK; Gouni-Berthold, I | 1 |
| Brada, M; Dohnalová, L; Edelsberger, T; Gerle, J; Haluzík, M; Houdová, J; Veselá, V | 1 |
| Boussageon, R; Cornu, C; Gueyffier, F | 1 |
| Boka, G; Niemoeller, E; Raccah, D; Seino, Y; Takami, A | 1 |
| Arnouts, P; De Broe, ME; Lalau, JD; Sharif, A | 1 |
| Bound, MJ; Checklin, H; Deacon, CF; Horowitz, M; Jones, KL; Ma, J; Rayner, CK; Wu, T | 1 |
| Shubrook, JH | 1 |
| Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A | 1 |
| Currie, CJ; Holden, SE | 1 |
| Bode, BW; Cirkel, DT; Perkins, CM; Perry, CR; Reinhardt, RR; Reusch, J; Stewart, MW; Ye, J | 1 |
| Bueno, M; Lecube, A; Suárez, X | 1 |
| Donohue, JM; Driessen, J; Gellad, WF; Marcum, ZA; Thorpe, CT | 1 |
| Bramlage, P; Gitt, AK; Schneider, S; Tschöpe, D | 1 |
| Gilbert, MP; Pratley, RE | 1 |
| Denton, BT; Herrin, J; Mason, JE; McCoy, RG; Montori, VM; Shah, ND; Smith, SA; Zhang, Y | 1 |
| Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Kiljański, J; Rosas-Guzmàn, J; Schernthaner, G; Simó, R; Zhou, M | 1 |
| Aguilar, R; Kushner, P; Shaefer, CF | 1 |
| Athanasiadou, E; Bekiari, E; Boura, P; Karagiannis, T; Liakos, A; Mainou, M; Matthews, DR; Paschos, P; Rika, M; Tsapas, A; Vasilakou, D | 1 |
| Carbone, MD; De Pergola, G; Giagulli, VA; Guastamacchia, E; Licchelli, B; Ramunni, MI; Sabbà, C; Triggiani, V | 1 |
| Hinnen, D | 1 |
| Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X | 1 |
| García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G | 1 |
| Cavun, S; Guclu, M; Gul, Z; Kisakol, G; Kiyici, S; Sigirli, D; Topyildiz, F | 1 |
| Everett, BM; Glynn, RJ; Goldfine, AB; Gopalakrishnan, C; Kim, SC; Liu, J; Patorno, E | 1 |
| Bongaerts, B; Kostev, K; Rathmann, W | 1 |
| Fu, AZ; Sheehan, JJ | 1 |
| Bahne, E; Brønden, A; Hansen, M; Knop, FK; Sonne, DP; Vilsbøll, T | 1 |
| Carlisle, SE; Mills, E; Smith, JD | 1 |
| Gamble, JM; Majumdar, SR; Midodzi, WK; Thomas, JM; Twells, LK | 1 |
| Rohde, U | 1 |
| Cahn, A; Cernea, S; Raz, I | 1 |
| Davis, TME; Thompson, PL | 1 |
| Caballero, AE | 1 |
| Caprio, M; Castellino, G; Ceriello, A; Genovese, S; Giglio, RV; Li Volti, G; Montalto, G; Nikolic, D; Patti, AM; Provenzano, V; Rizvi, AA; Rizzo, M | 1 |
| Gadde, KM; Hardy, E; Iqbal, N; Öhman, P; Vetter, ML | 1 |
| Cao, C; Marcinak, JF; Peng, XV; Raanan, MG | 1 |
| Manson, JE; Reusch, JE | 1 |
| Bezemer, ID; Bianchini, E; Blin, P; Hall, GC; Hammar, N; Heintjes, EM; Herings, RMC; Lapi, F; Lassalle, R; Overbeek, JA; Prieto-Alhambra, D | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Chandarana, K; Harris, S; Jaeckel, E; Jódar, E; Lingvay, I; Ranthe, MF | 1 |
| Kosiborod, M; Leiter, LA; Poulter, NR; Rajagopalan, S; Ray, K; Vora, J | 1 |
| Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
| Atherton, JJ; Montvida, O; Paul, SK; Shaw, J; Stringer, F | 1 |
| Agewall, S; Ceconi, C; Drexel, H; Kaski, JC; Kjeldsen, KP; Koller, L; Lewis, BS; Niessner, A; Rosano, G; Saely, CH; Savarese, G; Schmidt, TA; Tamargo, J; Torp-Pedersen, C; Walther, T; Wassmann, S | 1 |
| Chamarthi, B; Chen, L; Florez, JC; Goldfine, A; Hudson, M; Kaur, V; Littleton, KR; Manning, AK; Merino, J; Srinivasan, S; Thomas, MK | 1 |
| Gault, VA; Hölscher, C | 1 |
| Nathanson, D; Nyström, T | 1 |
| Chen, CC; Chen, XM; Qiu, CM; Tian, Y; Wang, LF; Zhang, WQ | 1 |
| Nakhleh, A; Raz, I; Shehadeh, N | 1 |
| Atherton, J; Green, JB; Montvida, O; Paul, SK | 1 |
| Altomari, A; Bonnet, F; Fassio, A; Gatti, D; Mantovani, A; Targher, G | 1 |
| Melidonis, A; Papanas, N; Papazafiropoulou, A; Xourgia, E | 1 |
| Aguirre, C; Arion, A; Ayala, I; Cárceles-Rodríguez, CM; Fernández-Varón, E; Martín-Gimenez, T; Rodríguez, MJ | 1 |
| Cusi, K | 1 |
| Choi, Y; Hur, KY; Jin, SM; Jun, JE; Ko, GP; Lee, MK; Lee, SE; Lee, YB | 1 |
| Pais, R; Ratziu, V | 1 |
| Geng, Z; Huang, Y; Shen, L; Wang, X; Wang, Y; Zhou, Y | 1 |
| Dankner, R; Roth, J | 1 |
| Greenfield, JR; Holmes-Walker, DJ; Snaith, JR | 1 |
| Jackuliak, P; Kužma, M; Payer, J | 1 |
| Abrahamowicz, M; Behlouli, H; Bernatsky, S; Elharram, M; Moura, CS; Pilote, L; Raparelli, V | 1 |
| Andreadou, I; Balampanis, K; Bamias, A; Birba, D; Dimitriadis, G; Ikonomidis, I; Iliodromitis, E; Kalogeris, A; Katogiannis, K; Kountouri, A; Kousathana, F; Lambadiari, V; Parissis, J; Pavlidis, G; Thymis, J | 1 |
| Cena, H; Chiovato, L; Nappi, RE | 1 |
| Han, R; Jia, S; Li, Y; Qin, X; Wang, Z; Xiang, R; Yang, J; Zhang, Z; Zhao, M | 1 |
| Bundgaard, JS; Christiansen, MN; Fosbøl, EL; Gislason, G; Kristensen, SL; Køber, L; Madelaire, C; Mogensen, UM; Rørth, R; Schou, M; Thein, D; Torp-Pedersen, C | 1 |
| Bain, A; Hadi, MA; Hasan, SS; Kavanagh, S; Kow, CS; Merchant, HA | 1 |
| Amadi, JA; Amadi, PU; Njoku, UC; Osuoha, JO | 1 |
| Lert-Itthiporn, W; Saengboonmee, C; Sanlung, T; Seubwai, W; Wongkham, S | 1 |
| Bergman, BK; Brown, K; Cui, X; Davies, MJ; Fernández Landó, L; Frías, JP; Liu, B; Pérez Manghi, FC; Rosenstock, J | 1 |
| Hyötyläinen, T; Jendle, J; Nyström, T; Orešič, M | 1 |
| Kimber-Trojnar, Ż; Niebrzydowska, M; Pilszyk, A; Pilszyk, Z; Wierzchowska-Opoka, M | 1 |
| Abramov, MA; Baislamov, AS; Chernousova, LM; Ishmuratova, AN; Ivanyuta, MV; Kitapova, AI; Kuznetsov, KO; Kuznetsova, AY; Mirgaliev, AA; Orozberdiev, ST; Shaihetdinova, AR; Shakirova, ZF; Usmonov, MD; Valeeva, LI; Yakupova, KI | 1 |
60 review(s) available for metformin and incretins
| Article | Year |
|---|---|
Management of type 2 diabetes in the obese patient: current concerns and emerging therapies.
Topics: Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Obesity; Risk Factors | 2008 |
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
Clinical management strategies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2007 |
[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].
Topics: Acarbose; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Gastrointestinal Tract; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin-Like Growth Factor I; Islet Amyloid Polypeptide; Metformin; Muscarinic Antagonists; Pirenzepine; Postprandial Period; Thiazolidinediones | 2008 |
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Drug evaluation: vildagliptin-metformin single-tablet combination.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipids; Metformin; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Safety; Treatment Outcome; Vildagliptin | 2009 |
[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Risk Factors; Satiety Response; Sitagliptin Phosphate; Triazoles; Weight Loss | 2010 |
Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?
Topics: Blood Glucose; Fatty Acids; Glucose Intolerance; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Metabolic Syndrome; Metformin; Myocardium; Prognosis; Risk Factors; Treatment Outcome | 2010 |
Add-on therapies to metformin for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Life Style; Metformin; Treatment Failure | 2011 |
Pharmacological management of type 2 diabetes: the potential of incretin-based therapies.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Metformin | 2011 |
Sitagliptin and metformin--novel combination therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Optimizing outcomes for GLP-1 agonists.
Topics: Algorithms; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2011 |
Insulin treatment for type 2 diabetes: when to start, which to use.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Metformin; Risk Factors | 2011 |
Type 2 diabetes mellitus: practical approaches for primary care physicians.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Incretins; Life Style; Mass Screening; Metformin; Physicians, Primary Care; Risk Assessment; Risk Factors | 2011 |
Recent diabetes issues affecting the primary care clinician.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency | 2011 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?
Topics: Algorithms; Decision Making; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Nurse Practitioners; Patient Satisfaction; Power, Psychological; Time Factors | 2012 |
Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Combinations; Drug Costs; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Medication Adherence; Metformin; Quality of Life; Sulfonylurea Compounds; Treatment Outcome | 2013 |
Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Treatment Outcome; Weight Loss | 2013 |
Obesity and diabetes.
Topics: Animals; Cyclobutanes; Diabetes Mellitus; Female; Humans; Incretins; Insulin; Lactones; Male; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Sex Characteristics; Sulfonylurea Compounds | 2012 |
Antidiabetic therapy effects on bone metabolism and fracture risk.
Topics: Aging; Animals; Bone Density; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Fractures, Bone; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Osteocalcin; Osteoporosis; PPAR gamma; Risk Factors; Signal Transduction; Thiazolidinediones; Wnt Proteins | 2013 |
Use of noninsulin antidiabetic medications in hospitalized patients.
Topics: Benzamides; Biguanides; Bromocriptine; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glycoside Hydrolase Inhibitors; Hospitalization; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Islet Amyloid Polypeptide; Metformin; Sulfonylurea Compounds; Thiazolidinediones | 2013 |
Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Metformin; Randomized Controlled Trials as Topic | 2013 |
[Management of type 2 diabetes: new or previous agents, how to choose?].
Topics: Administration, Oral; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Goals; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Kidney; Metformin; Obesity; Practice Guidelines as Topic; Risk; Societies, Medical; Sulfonylurea Compounds | 2013 |
Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Topics: Algorithms; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Metformin; Peptides; Piperidines; Practice Guidelines as Topic; Receptors, Glucagon; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2013 |
Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Neoplasms; Obesity; Risk Factors; Thiazolidinediones | 2013 |
Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Coronary Artery Disease; Female; Humans; Hypertension; Incretins; Insulin Resistance; Life Style; Metformin; Middle Aged; Obesity; Polycystic Ovary Syndrome; Postmenopause; Renin-Angiotensin System; Risk Factors; Sleep Apnea, Obstructive; Thiazolidinediones; Vascular Stiffness; Weight Reduction Programs | 2013 |
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents.
Topics: Adipokines; Adipose Tissue; Animals; Anti-Obesity Agents; Azetidines; Ezetimibe; Fibric Acids; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Incretins; Insulin; Insulin Resistance; Lipids; Lipoproteins; Metabolic Syndrome; Metformin; Niacin; Thiazolidinediones | 2014 |
Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome.
Topics: Acarbose; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Incretins; Insulin; Metabolic Syndrome; Metformin; Risk Reduction Behavior; Thiazolidinediones | 2014 |
Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2014 |
Metformin and other antidiabetic agents in renal failure patients.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Kidney Transplantation; Metformin; Renal Insufficiency; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Metformin; Receptors, Glucagon | 2014 |
[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Female; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Venoms; Weight Loss | 2014 |
The impact of diabetes and diabetes medications on bone health.
Topics: Bone and Bones; Bone Density; Bone Remodeling; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fractures, Bone; Hip Fractures; Humans; Hypoglycemic Agents; Incretins; Insulin; Islet Amyloid Polypeptide; Metformin; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Medication Adherence; Metformin; Pancreas; Primary Health Care; Weight Loss | 2015 |
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Incretins; Male; Metformin; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Venoms | 2015 |
Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.
Topics: Age Factors; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Kidney; Metformin | 2015 |
Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin.
Topics: Bile Acids and Salts; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metformin | 2016 |
Treatment of Pediatric Type 2 Diabetes.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2016 |
EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Topics: Animals; Bariatric Surgery; Bile Acids and Salts; Cholecystokinin; Diabetes Mellitus, Type 2; Gastric Bypass; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glycated Hemoglobin; Humans; Incretins; Metformin; Obesity; Weight Loss | 2016 |
An update on DPP-4 inhibitors in the management of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Design; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2017 |
Long-term studies of treatments for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonylurea Compounds; Thiazolidinediones | 2017 |
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Nitriles; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Risk Factors; Venoms; Vildagliptin | 2017 |
Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Neoplasms; Risk Factors; Thiazolidinediones | 2017 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes.
Topics: Animals; Blood Glucose; Brain; Cognition; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Metformin; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress | 2018 |
Anti-diabetic treatment leads to changes in gut microbiome.
Topics: alpha-Glucosidases; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dysbiosis; Fermentation; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipid Metabolism; Metformin; Mice; Obesity; Permeability; Polysaccharides; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Metformin; Prognosis; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
Topics: Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Protective Factors; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urinary Bladder Neoplasms | 2020 |
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Topics: Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Incretins; Metformin; Outcome Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of antidiabetic treatment on bone.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Osteoporosis; Sulfonylurea Compounds; Thiazolidinediones | 2019 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, Female; Liraglutide; Metformin; Obesity; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Testosterone; Treatment Outcome; Weight Loss | 2020 |
Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Metformin; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients.
Topics: Adrenal Cortex Hormones; Blood Glucose; Comorbidity; COVID-19; Deprescriptions; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Susceptibility; Glycemic Control; Hospitalization; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Metformin; Monitoring, Physiologic; Patient Care Planning; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2021 |
Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication.
Topics: Blood Glucose; Case-Control Studies; Cholangiocarcinoma; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Sulfonylurea Compounds | 2021 |
Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glyburide; Humans; Hypoglycemic Agents; Incretins; Metformin; Pregnancy | 2022 |
[The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review].
Topics: Alzheimer Disease; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin; Middle Aged; Observational Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Thiazolidinediones | 2023 |
20 trial(s) available for metformin and incretins
| Article | Year |
|---|---|
Exenatide versus glibenclamide in patients with diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Exenatide; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Proinsulin; Resistin; Retinol-Binding Proteins, Plasma; Venoms; Young Adult | 2010 |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; E-Selectin; F2-Isoprostanes; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Metformin; Middle Aged; Oxidative Stress; Piperidines; Postprandial Period; Time Factors; Treatment Outcome; Wales | 2011 |
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Peptides | 2013 |
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
Topics: Adamantane; Aged; Aged, 80 and over; Analysis of Variance; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Thiazolidinediones; Treatment Outcome | 2013 |
Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gene Expression Regulation; Glucose; Humans; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
[Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
Topics: Adamantane; Adult; Aged; Cohort Studies; Czech Republic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Vildagliptin; Weight Gain | 2013 |
Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.
Topics: Adult; Aged; Asian People; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Japan; Male; Metformin; Middle Aged; Peptides; Receptors, Glucagon; Sulfonylurea Compounds; White People; Young Adult | 2014 |
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Energy Intake; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Topics: Aged; Biomarkers; Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Europe; Exenatide; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemic Agents; Incretins; Lipids; Male; Metformin; Middle Aged; Peptides; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Venoms | 2015 |
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins | 2016 |
Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Down-Regulation; Drug Therapy, Combination; Eating; Exenatide; Female; Ghrelin; Humans; Hypoglycemic Agents; Incretins; Metformin; Middle Aged; Obesity; Peptides; Postprandial Period; Prospective Studies; Time Factors; Treatment Outcome; Venoms; Weight Loss | 2016 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Echocardiography, Doppler, Color; Female; Humans; Hypoglycemic Agents; Incretins; Italy; Liraglutide; Male; Metabolic Syndrome; Metformin; Middle Aged; Predictive Value of Tests; Prevalence; Prospective Studies; Risk Factors; Treatment Outcome | 2016 |
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Excipients; Exenatide; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incidence; Incretins; Injections, Jet; Male; Metformin; Middle Aged; Peptides; Sitagliptin Phosphate; Triglycerides; United States; Venoms | 2017 |
Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Topics: Benzofurans; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Hemoglobins, Abnormal; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Incretins; Male; Metformin; Middle Aged; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Sulfones; United States | 2017 |
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; Drug Monitoring; Drug Resistance, Multiple; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Metformin; Obesity; Overweight; Weight Gain; Weight Loss | 2018 |
Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
Topics: Administration, Oral; Adult; Biomarkers; China; Diabetes Mellitus, Type 2; Down-Regulation; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Time Factors; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2018 |
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatme
Topics: Adult; Aged; Arterial Pressure; Arteries; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelial Cells; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycocalyx; Greece; Humans; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Ventricular Function, Left | 2020 |
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Male; Metformin; Middle Aged; Nausea; Weight Loss | 2021 |
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Topics: Aged; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Lipidomics; Lipids; Liraglutide; Male; Metabolome; Metabolomics; Metformin; Middle Aged; Spectrometry, Mass, Electrospray Ionization; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2021 |
44 other study(ies) available for metformin and incretins
| Article | Year |
|---|---|
Exenatide: new drug. Type 2 diabetes for some overweight patients.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Metformin; Overweight; Peptides; Sulfonylurea Compounds; Venoms; Weight Gain; Weight Loss | 2007 |
DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metformin; Protease Inhibitors; Thiazolidinediones | 2008 |
[Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Insulin; Metformin; Patient Education as Topic; Patient Selection; Peptides; Venoms | 2008 |
New therapeutic options: management strategies to optimize glycemic control.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Addition of incretin therapy to metformin in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metformin | 2010 |
Individualised incretin-based treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Part D coverage gap and adherence to diabetes medications.
Topics: Aged; Cohort Studies; Confidence Intervals; Diabetes Mellitus; Female; Glucagon-Like Peptide 1; Health Services Accessibility; Humans; Hypoglycemic Agents; Incretins; Insulin; Insurance Claim Review; Insurance Coverage; Male; Medicare Part D; Medication Adherence; Metformin; Odds Ratio; Retrospective Studies; Sulfonylurea Compounds; Thiazolidinediones; United States | 2010 |
The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged | 2012 |
Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
Topics: Aged; Body Mass Index; Dipeptidyl Peptidase 4; Drug Monitoring; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Outpatient Clinics, Hospital; Patient Acceptance of Health Care; Peptides; Retrospective Studies; Treatment Outcome; Venoms | 2012 |
A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Metformin | 2013 |
Incretin-based therapy compared with non-insulin alternatives in elderly patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incretins; Metformin; Sulfonylurea Compounds; Thiazolidinediones | 2013 |
Prescribing of antidiabetic therapies in Ireland: 10-year trends 2003-2012.
Topics: Age Factors; Aged; Databases, Factual; Diabetes Mellitus; Drug Prescriptions; Female; Humans; Hypoglycemic Agents; Incretins; Insulin; Ireland; Male; Metformin; Middle Aged; Sex Factors; Young Adult | 2014 |
Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Topics: Blood Glucose; Body Weight; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Myocardial Infarction; Retrospective Studies; Stroke; Sulfonylurea Compounds; Treatment Outcome | 2014 |
Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Sulfonylurea Compounds | 2014 |
Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Incretins; Male; Medicare Part D; Metformin; Sulfonylurea Compounds; Thiazolidinediones; United States | 2015 |
A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Prospective Studies; Registries; Sulfonylurea Compounds; Treatment Outcome | 2015 |
Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insurance Claim Review; Male; Metformin; Middle Aged; Residence Characteristics; Retrospective Studies; Sex Factors; Socioeconomic Factors; Sulfonylurea Compounds; United States; Young Adult | 2015 |
Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erectile Dysfunction; Glycated Hemoglobin; Hormone Replacement Therapy; Humans; Hypoglycemic Agents; Hypogonadism; Incretins; Liraglutide; Male; Metformin; Middle Aged; Obesity; Penile Erection; Retrospective Studies; Risk Reduction Behavior; Testosterone; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Lipids; Liraglutide; Liver Function Tests; Male; Metabolic Syndrome; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Peptides; Pilot Projects; Pioglitazone; Prospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Venoms; Waist Circumference | 2016 |
Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
Topics: Adult; Angina, Unstable; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Hospitalization; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stroke; Sulfonylurea Compounds | 2016 |
Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
Topics: Aged; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Odds Ratio; Primary Health Care; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Retrospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Failure; Young Adult | 2016 |
Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Management of Type 2 Diabetes in 2017: Getting to Goal.
Topics: Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Management; Glycated Hemoglobin; Goals; Healthy Lifestyle; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Metformin; Patient-Centered Care; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.
Topics: Aged; Carbamates; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug Utilization; Europe; Female; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Piperidines; Sulfonylurea Compounds | 2017 |
Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Longitudinal Studies; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Time Factors; Young Adult | 2018 |
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Topics: Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Europe; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Metformin; Myocardial Infarction; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors; Stroke | 2018 |
Topics: Adult; Aged; Alleles; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotyping Techniques; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Metformin; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Risk Factors; Sulfonylurea Compounds; Transcription Factor 7-Like 2 Protein | 2018 |
Topics: Algorithms; Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Incretins; Insulin; Insulin Resistance; Life Style; Metformin; Practice Guidelines as Topic; Sulfonylurea Compounds | 2018 |
Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Metformin; Protective Factors; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Topics: Acute Disease; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Pancreatic Diseases; Pancreatic Neoplasms; Pancreatitis | 2019 |
Association between increased carotid intima-media thickness and higher serum C-terminal telopeptide of type 1 collagen levels in post-menopausal women with type 2 diabetes.
Topics: Absorptiometry, Photon; Adaptor Proteins, Signal Transducing; Aged; Bone Density; Bone Remodeling; Carotid Intima-Media Thickness; Carotid Stenosis; Cell Adhesion Molecules; Collagen Type I; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incretins; Intercellular Signaling Peptides and Proteins; Metformin; Peptide Fragments; Peptides; Postmenopause; Procollagen; RANK Ligand; Sulfonylurea Compounds; Ultrasonography, Doppler | 2020 |
Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration.
Topics: Animals; Horses; Hypoglycemic Agents; Incretins; Insulin; Metformin; Sitagliptin Phosphate | 2019 |
Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Incretins; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fiber; Feces; Female; Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Incretins; Insulin; Lipopolysaccharides; Male; Metformin; Middle Aged; Pilot Projects; Sulfonylurea Compounds; Treatment Outcome | 2019 |
Editorial: it is not a wide-open field for incretins - collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis.
Topics: Diabetes Mellitus; Humans; Incretins; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease | 2019 |
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Retrospective Studies; Risk Assessment; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Topics: Aged; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Patient Admission; Registries; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2020 |
Potentiation of incretin hormones and modulation of metabolic enzymes as possible mechanisms behind the insulin sensitizing effects of cabbage-metformin treatment.
Topics: Animal Feed; Animals; Brassica; Diet; Dietary Carbohydrates; Fructose; Hypoglycemic Agents; Incretins; Insulin Resistance; Male; Metformin; Rats; Rats, Wistar | 2021 |